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The establishment of candidate genes associated with susceptibility to TB is a challenge
especially due to divergent frequencies among different populations. The objective of this
study was to evaluate the association between macrophage migration inhibitory factor (MIF)
-173 G>C single nucleotide polymorphism (SNP) and susceptibility to pulmonary TB in a
population of southern Brazil.
Methods
Case-control study. Patients > 18 years old, diagnosed with pulmonary TB were included.
The control group consisted of blood donors and household contacts, not relatives, healthy
and > 18 years old. MIF -173 G>C SNPs were genotyped using real-time PCR using a Taq-
Man SNP Genotyping assay.
Results
174 patients and 166 controls were included. There were no statistically significant differ-
ences between cases and controls regarding genotype prevalence (p>0.05). Comparing
patients with normal genotype (GG) with those with at least one C allele, there was also no
statistically significant difference (p = 0.135). Also, there was no statistically significant differ-
ence comparing the homozygous for the mutation (CC) with the other patients (GG and CG)
(p = 0.864).
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Conclusions
We did not find association between MIF -173 G>C polymorphism and susceptibility to pul-
monary TB.
Introduction
The natural history of tuberculosis (TB) follows a variable course after the initial infection,
with only 10% of infected individuals actually developing clinical disease. Genetic, environ-
mental and bacterial virulence factors can influence the clinical presentation of TB [1]. Many
studies indicate that genetic factors play a major role in determining the susceptibility and
resistance to TB [2–5].
Polymorphisms of genes play an important role in the occurrence and development of TB.
In recent years, many TB susceptibility genes have been detected [6–13]. The macrophage
migration inhibitory factor (MIF) is a cytokine with proinflammatory chemokine-like func-
tions that have been recognized to play a central role in mediating a wide variety of immune
responses against invading pathogens, and may be associated with the onset and / or progres-
sion of TB. In a fact, a metanalysis revealed a strong association of a MIF polymorphism with
autoimmune and infectious diseases [14]. In TB, MIF is probably the first cytokine to appear
in inflammatory response, inhibits macrophage migration, and promotes macrophage accu-
mulation and T lymphocytes activation in inflamed TB lesions [15,16]. Four polymorphisms
were identified in the MIF gene; however, only the MIF-173 and MIF (CATT5-8) are related to
changes on MIF levels [17]. A few studies had evaluated these polymorphisms in TB, in differ-
ent populations, with controversial results [16,18–22].
The establishment of candidate genes associated with susceptibility to TB is a challenge
especially due to divergent frequencies among different populations [23]. Therefore, studies
on the relationship between the susceptibility to TB and genetic polymorphisms in various
populations and ethnic groups are of great importance. The objective of this study was to eval-
uate, in a case-control study, the association between MIF -173 G>C single nucleotide poly-
morphism (SNP) and susceptibility to pulmonary TB in a population of southern Brazil.
Materials and methods
Study design and location
This study was a case-control study done on 174 patients and 166 controls and conducted in
two hospitals in a city in Southern Brazil with high incidence of TB (80.4 cases/100,000 inhabi-
tants) [24]: Hospital de Clı́nicas de Porto Alegre, a tertiary hospital, university-affiliated, with
750 beds and about 300 cases of TB treated per year, and Hospital Sanatório Partenon, a refer-
ral hospital for TB treatment. The study was conducted between 2016 and 2019. The study was
approved by the Research Ethics Committee of Hospital de Clı́nicas de Porto Alegre (number
16–0599), and all research was in accordance with regulations. All cases and controls signed
Informed Consent Form prior to inclusion in the study.
Patients
We included patients > 18 years old, diagnosed with pulmonary TB, during any time between
the diagnosis and completion of treatment. Patients with concomitant extrapulmonary TB
were excluded. The control group consisted of blood donors and household contacts, not
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relatives, healthy and > 18 years old. Cases and controls were negative for human immunode-
ficiency virus (HIV), and hepatitis B and C virus (HBV and HCV).
Data collection
Patients were interviewed using a standardized questionnaire. The following data were
recorded: demographic data (gender, age, race, years of schooling); presence of symptoms;
smoking history; alcohol and drug abuse, and comorbidities. The racial and ethnic composi-
tion of Brazilian society is the result of a confluence of people from many different ethnic back-
grounds: the original indigenous people, black Africans, Portuguese settlers, and later,
European, Arab and Japanese immigrants, as well as other Asian people and from South
American countries [25]. We collected data on race and classified patients in white and non-
white. The diagnosis of pulmonary TB was accomplished through chest radiography, sputum
smear and culture for mycobacteria, and based on consensus criteria [26]. All patients used the
same treatment (the standard treatment in Brazil: rifampicin, isoniazid, ethambutol, and
pyrazinamide).
DNA extraction
Whole blood samples were collected in EDTA tubes. Total genomic DNA was isolated from
peripheral blood leukocytes by the salting out method [27] and stored at -20˚C until analysis.
MIF Genotyping-173 G> C
The MIF -173 G>C polymorphism (rs755622) was genotyped by real-time polymerase chain
reaction (RT-PCR) using a TaqMan SNP Genotyping assay (part number C_2213785_10;
Applied Biosystems, Foster City, CA, USA), according to a protocol of Gomez et al [16], using
StepOne ™ Real-Time PCR Systems. The PCR was carried out with mixes consisting of 8 ng of
genomic DNA, 2.5 ml of Taqman master mix, 0.125 μl of 20 X assay mix and ddH2O up to 5 μl
of final volume. The amplification protocol used was 50˚C for 2 min and initial denaturation
at 95˚C for 10 min followed by 50 cycles of denaturation at 92ºC for 15 s and annealing/exten-
sion at 60˚C for 1 min [16].
Statistical analysis
Data analysis was performed using SPSS 18.0 (Statistical Package for the Social Sciences, Chi-
cago, Illinois). Genotypic frequencies were tested for Hardy-Weinberg using the chi-square
test. Frequencies of genotypes and alleles were compared between cases and controls by logis-
tic regression with adjustment for gender and age. Odds ratio (OR) was used as the point esti-
mates of risk and was calculated along with their 95% confidence intervals (95% CI). P value
less than 0.05 was considered as statistically significant. Considering data of a previous study
[20], with confidence interval of 95% and a power of 80%, at least 83 cases and 83 controls will
be needed.
Results
During the study period, 174 patients and 166 controls met the inclusion criteria and were
included in the analysis. The age range was 18–78 years (cases) and 18–61 years (controls).
There were 120 (69.0%) males and 54 (31.0%) females among cases and 105 (63.3%) males and
61 (36.7%) females among controls. One hundred and fifteen patients were white (66.1%) and
59 (33.9%) were non-white among cases and 114 (68.7%) were white and 52 (31.3%) were
non-white among controls. The prevalence of genotypes GG (normal), GC (heterozygous),
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and CC (homozygous for mutation) among cases was 94 (54.0%), 72 (41.4%), and 8 (4.6%),
respectively. In controls, the frequencies of genotypes GG (normal), GC (heterozygous), and
CC (homozygous for mutation) among cases were 103 (62.1%), 56 (33.7%), and 7 (4.2%),
respectively. The genotype frequencies were not found to be significantly different from those
predicted by the Hardy–Weinberg equilibrium. There were no statistically significant differ-
ences between cases and controls regarding genotype prevalence, controlled for age and sex
(Table 1).
Comparing patients with normal genotype (GG) with those with at least one C allele, there
was also no statistically significant difference (p = 0.135). In addition, there was no statistically
significant difference comparing the homozygous for the mutation (CC) with the other
patients (GG and CG) (p = 0.864).
Discussion
In the present study, we did not find association between MIF -173 G>C polymorphism and
susceptibility to pulmonary TB. There were no statistically significant differences between
cases and controls regarding genotype prevalence. In addition, there was no statistically signifi-
cant difference comparing patients with normal genotype (GG) with those with at least one C
allele, and comparing the homozygous for the mutation (CC) with the other patients (GG and
CG).
There is increasing evidence that host genetic factors are implicated in susceptibility to TB,
corroborated by monozygotic and dizygotic twin studies [5,28], genome-wide linkage studies
[29–31], and genome-wide association studies [32,33]. Polymorphisms in candidate genes
have shown influence on this TB susceptibility. MIF -173 G>C gene polymorphism has been
shown to play a role in TB risk in several studies [16,18–22]. MIF gene is located at
chromosome22q11�2 and encodes a T-cell-derived cytokine that plays an important role acti-
vating macrophage functions, regulating Th1/Th2 balance, and also is involved in delayed-
type hypersensitivity reaction [34–36]. MIF is expressed by epithelial cells of the bronchi and
alveolar macrophages, which have substantial influence on defense against tubercle bacilli
[37]. In a Ugandan cohort, it was showed that genetic low expressers of MIF were 2.4-times
more frequently identified among patients with Mycobacterium tuberculosis bacteremia than
those without. Also, MIF deficient mice have an inadequate innate immune response and, con-
sequently, are more susceptible to mycobacterial pathology [38].
Table 1. Genotype frequency of MIF -137 G/C polymorphism in cases and controls.
Genetic model Cases, n (%) Controls, n (%) OR (95% CI) P value
Codominant
GG 94 (54.0) 103 (62.1) 1.00 (reference)
GC 72 (41.4) 56 (33.7) 0.71 (0.45–1.11) 0.133
CC 8 (4.6) 7 (4.2) 0.79 (0.28–2.29) 0.675
Dominant
GG 94 (54.0) 103 (62.1) 1.00 (reference)
GC + CC 80 (46.0) 63 (37.9) 0.72 (0.47–1.11) 0.135
Recessive
GG + GC 166 (95.4) 159 (95.8) 1.00 (reference)
CC 8 (4.6) 7 (4.2) 1.09 (0.39–3.09) 0.864
Allele
C 88 (25.3) 70 (21.1) - 0.195
G 260 (74.7) 262 (78.9) - 0.195
https://doi.org/10.1371/journal.pone.0234565.t001
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We did not find differences in MIF -173 G>C genotype prevalence comparing patients
with TB and the control group. Gomez et al [16] studied 230 northwestern Colombian patients
with pulmonary TB, negative for HIV, and 235 matched healthy individuals, and found on
multivariate analysis that MIF -173C allele was associated with disease (odds ratio = 1.64) in a
dominant pattern. In a Moroccan population, the authors demonstrated a statistically signifi-
cant increase of the MIF –173CC homozygote genotype and MIF –173�C allele frequencies in
PTB patients compared with healthy controls [21]. Hashemi et al [18], showed in an Iranian
population that the MIF -173 G/C polymorphism increased the risk of PTB in codominant
(GC vs GG, OR = 1.76) and dominant (GC+CC vs GG, OR = 1.78) tested models. Three stud-
ies were conducted in Chinese population. One of them [19] evidenced that distribution of
MIF -173 genotypes (GC + CC) was significantly higher in TB cases than in controls, and the
frequencies for MIF -173 (GG vs. GC+CC) were statistically significant different comparing
total cases of TB, new cases of TB, and retreatment cases of TB to controls, respectively. Yanlin
et al [22] demonstrated that the frequency of MIF -173 (GC + CC) was higher in TB patients
than in controls (OR = 2.12). Last, Kuai et al [20] found a significant association of MIF -173 C
alleles with susceptibility to active TB. Since polymorphisms occur at different frequencies in
populations of different ethnicities, the high prevalence of miscegenation in our country may
have contributed to these results [25]. In addition, one should also consider the fact that the
population of southern Brazil (study setting) has Italian and German descent, and that these
polymorphisms have not been demonstrated in these populations, only in Chinese [19,20,22],
Moroccan [21], Colombian [16], and Iranian [18] populations. In addition, the sample size
could be small to come to a conclusion at this point; however, we calculated a priori sample
size, and it is bigger than 3 out of 6 studies conducted on this topic.
One limitation of this study is that we recruited patients from a single region of Brazil, and,
as stated above, it is well known that Brazil is an extensive country with a varied ethnic and
racial composition. Therefore, this may have prevented us from finding differences in geno-
type frequency.
This study has been conducted in mixed population, as both cases and control study sub-
jects consists of peoples from various ethnic origin. An elaborated study with a larger sample
size is required to bring enough power to analyse the data from different ethnic groups. In
addition, we didn’t collect data on body mass index (BMI), and it is well known that low BMI
could contribute to TB disease establishment. Also, the patients were not followed-up after the
treatment for relapse. Furthermore, we know that a cohort study including patients with MIF
polymorphism and evaluating the development of TB would bring better scientific evidence;
however, this kind of study is expensive and take a lot of time to get results. Moreover, MIF
levels were not quantified; a correlation study between different genotypes and MIF levels in
patients and controls might help to explain the association between MIF -173 G>C gene poly-
morphism and susceptibility/resistance to tuberculosis. In spite of these concerns, this is the
first study to evaluate the association between MIF -173 G>C polymorphism and susceptibil-
ity to pulmonary TB in Brazil.
In conclusion, in the present study, there were no differences in MIF -173 G>C genotype
prevalence when comparing TB cases and controls. Further studies, including patients from
various regions of Brazil are necessary to better evaluate the association between MIF -173
G>C polymorphism and susceptibility to pulmonary TB.
Author Contributions
Conceptualization: Mirela Gehlen, Elis Regina Dalla Costa, Maria Lucia Rosa Rossetti, Denise
Rossato Silva.
PLOS ONE MIF -173 G>C SNP in tuberculosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0234565 June 11, 2020 5 / 8
Formal analysis: Mirela Gehlen, Elis Regina Dalla Costa, Maria Lucia Rosa Rossetti, Denise
Rossato Silva.
Funding acquisition: Denise Rossato Silva.
Investigation: Mirela Gehlen, Elis Regina Dalla Costa, Denise Rossato Silva.
Methodology: Mirela Gehlen, Maria Lucia Rosa Rossetti, Denise Rossato Silva.
Project administration: Mirela Gehlen, Elis Regina Dalla Costa, Maria Lucia Rosa Rossetti,
Denise Rossato Silva.
Supervision: Denise Rossato Silva.
Writing – original draft: Mirela Gehlen, Denise Rossato Silva.
Writing – review & editing: Mirela Gehlen, Elis Regina Dalla Costa, Maria Lucia Rosa
Rossetti.
References
1. Raviglione MC, Kochi A, Snider DE. Global Epidemiology of Tuberculosis: Morbidity and Mortality of a
Worldwide Epidemic. JAMA J Am Med Assoc. 1995; 273:220–6.
2. van de Vosse E, Hoeve MA, Ottenhoff THM. Human genetics of intracellular infectious diseases: molec-
ular and cellular immunity against mycobacteria and salmonellae. Lancet Infect Dis [Internet]. 2004
[cited 2019 Oct 21]; 4:739–49. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15567123 https://
doi.org/10.1016/S1473-3099(04)01203-4 PMID: 15567123
3. Hill A. The genomics and genetics of human infectious disease susceptibility.—PubMed—NCBI [Inter-
net]. Annu Rev Genomics Hum Genet. 2001 [cited 2019 Oct 21]. p. 373–400. Available from: https://
www.ncbi.nlm.nih.gov/pubmed/11701655 https://doi.org/10.1146/annurev.genom.2.1.373 PMID:
11701655
4. Bellamy R. Genetic susceptibility to tuberculosis. Clin Chest Med [Internet]. 2005 [cited 2019 Oct 21];
26:233–46, vi. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15837108 https://doi.org/10.1016/j.
ccm.2005.02.006 PMID: 15837108
5. Comstock GW. Tuberculosis in twins: a re-analysis of the Prophit survey. Am Rev Respir Dis [Internet].
1978 [cited 2019 Oct 21]; 117:621–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/565607
https://doi.org/10.1164/arrd.1978.117.4.621 PMID: 565607
6. Vasilca V, Oana R, Munteanu D, Zugun F, Constantinescu D, Carasevici E. HLA-A and -B phenotypes
associated with tuberculosis in population from north-eastern Romania. Roum Arch Microbiol Immunol
[Internet]. [cited 2019 Oct 21]; 63:209–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/
17240790
7. Yim J-J, Selvaraj P. Genetic susceptibility in tuberculosis. Respirology [Internet]. 2010 [cited 2019 Oct
21]; 15:241–56. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20199642 https://doi.org/10.
1111/j.1440-1843.2009.01690.x PMID: 20199642
8. Malik S, Abel L, Tooker H, Poon A, Simkin L, Girard M, et al. Alleles of the NRAMP1 gene are risk fac-
tors for pediatric tuberculosis disease. Proc Natl Acad Sci U S A [Internet]. 2005 [cited 2019 Oct 21];
102:12183–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16103355 https://doi.org/10.1073/
pnas.0503368102 PMID: 16103355
9. Dissanayeke SR, Levin S, Pienaar S, Wood K, Eley B, Beatty D, et al. Polymorphic variation in TIRAP is
not associated with susceptibility to childhood TB but may determine susceptibility to TBM in some eth-
nic groups. PLoS One [Internet]. 2009 [cited 2019 Oct 21]; 4:e6698. Available from: http://www.ncbi.
nlm.nih.gov/pubmed/19693265 https://doi.org/10.1371/journal.pone.0006698 PMID: 19693265
10. Liu W, Cao WC, Zhang CY, Tian L, Wu XM, Habbema JDF, et al. VDR and NRAMP1 gene polymor-
phisms in susceptibility to pulmonary tuberculosis among the Chinese Han population: a case-control
study. Int J Tuberc Lung Dis [Internet]. 2004 [cited 2019 Oct 21]; 8:428–34. Available from: http://www.
ncbi.nlm.nih.gov/pubmed/15141734 PMID: 15141734
11. El Sahly HM, Reich RA, Dou SJ, Musser JM, Graviss EA. The effect of mannose binding lectin gene
polymorphisms on susceptibility to tuberculosis in different ethnic groups. Scand J Infect Dis [Internet].
2004 [cited 2019 Oct 21]; 36:106–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15061663
https://doi.org/10.1080/00365540310018860 PMID: 15061663
PLOS ONE MIF -173 G>C SNP in tuberculosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0234565 June 11, 2020 6 / 8
12. Tosh K, Campbell SJ, Fielding K, Sillah J, Bah B, Gustafson P, et al. Variants in the SP110 gene are
associated with genetic susceptibility to tuberculosis in West Africa. Proc Natl Acad Sci U S A [Internet].
2006 [cited 2019 Oct 21]; 103:10364–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/
16803959 https://doi.org/10.1073/pnas.0603340103 PMID: 16803959
13. Velez DR, Hulme WF, Myers JL, Weinberg JB, Levesque MC, Stryjewski ME, et al. NOS2A, TLR4, and
IFNGR1 interactions influence pulmonary tuberculosis susceptibility in African-Americans. Hum Genet
[Internet]. 2009 [cited 2019 Oct 21]; 126:643–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/
19575238 https://doi.org/10.1007/s00439-009-0713-y PMID: 19575238
14. Illescas O, Gomez-Verjan JC, Garcı́a-Velázquez L, Govezensky T, Rodriguez-Sosa M. Macrophage
migration inhibitory factor -173 G/C polymorphism: A global meta-analysis across the disease spec-
trum. Front Genet. 2018; 9:1–14. https://doi.org/10.3389/fgene.2018.00001
15. Nishihira J. Macrophage migration inhibitory factor (MIF): Its essential role in the immune system and
cell growth. J. Interf. Cytokine Res. 2000. p. 751–62.
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